AAP
CTMX icon

Arax Advisory Partners’s CytomX Therapeutics CTMX Stock Holding History

Arax Advisory Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$356 Buy
+95
New +$363 ﹤0.01% 5047

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Arax Advisory Partners's CTMX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in CytomX Therapeutics (CTMX) in Q2 2026: 95 shares worth $356. The stake represents ﹤0.01% of the portfolio and ranks #5047 among its holdings.

179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Arax Advisory Partners held 95 shares of CytomX Therapeutics worth $356 as of Q2 2026.
  • CytomX Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • CytomX Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5047 holding.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.